TREM2 Microglia Pathway in Alzheimer's Disease

Migration, Crosslink

📖

TREM2 Microglia Pathway in Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-trem2-microglia-pathway-

📖 Wiki Page

mechanism2264 wordssynced 2026-04-02

TREM2 Microglia Pathway in Alzheimer's Disease

Introduction

Trem2 [Microglia](/cell-types/microglia-neuroinflammation) Pathway In Alzheimer'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor primarily expressed on [microglia](/entities/microglia) in the central nervous system. Rare coding variants in [TREM2](/proteins/trem2) (including R47H, R62H, D87N, and Y38C) increase Alzheimer's disease (AD) risk by approximately 2-4 fold, similar to the effect of one [APOE](/proteins/apoe) ε4 allele. This page details the biology of TREM2, its role in microglial function, disease-associated microglia (DAM) activation, and therapeutic targeting strategies. [@ulrich2016]

TREM2 Biology

Gene and Protein Structure

The TREM2 gene (located on chromosome 6p21.1) encodes a type I transmembrane protein with: [[Wang et al., TREM2 mediates microglial phagocytosis (2015)](https://pubmed.ncbi.nlm.nih.gov/26028526/)]

Extracellular Ig-like V-type domain (ligand binding)
Single transmembrane helix
Cytoplasmic tail with ITAM motif (via DAP12 adaptor)

Expression Pattern

Highest expression in microglia within the brain
Also expressed in peripheral macrophages, dendritic cells, and osteoclasts
Upregulated in AD brain, particularly around amyloid plaques

Signaling Mechanisms

DAP12 Adaptor Protein

...

TREM2 Microglia Pathway in Alzheimer's Disease

Introduction

Trem2 [Microglia](/cell-types/microglia-neuroinflammation) Pathway In Alzheimer'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor primarily expressed on [microglia](/entities/microglia) in the central nervous system. Rare coding variants in [TREM2](/proteins/trem2) (including R47H, R62H, D87N, and Y38C) increase Alzheimer's disease (AD) risk by approximately 2-4 fold, similar to the effect of one [APOE](/proteins/apoe) ε4 allele. This page details the biology of TREM2, its role in microglial function, disease-associated microglia (DAM) activation, and therapeutic targeting strategies. [@ulrich2016]

TREM2 Biology

Gene and Protein Structure

The TREM2 gene (located on chromosome 6p21.1) encodes a type I transmembrane protein with: [[Wang et al., TREM2 mediates microglial phagocytosis (2015)](https://pubmed.ncbi.nlm.nih.gov/26028526/)]

Extracellular Ig-like V-type domain (ligand binding)
Single transmembrane helix
Cytoplasmic tail with ITAM motif (via DAP12 adaptor)

Expression Pattern

Highest expression in microglia within the brain
Also expressed in peripheral macrophages, dendritic cells, and osteoclasts
Upregulated in AD brain, particularly around amyloid plaques

Signaling Mechanisms

DAP12 Adaptor Protein

Mermaid diagram (expand to render)

Key Signaling Pathways

PI3K/AKT: Cell survival, metabolic regulation

MAPK/ERK: Gene transcription, cell proliferation

NF-κB: Inflammatory gene expression

Calcium mobilization: Cytoskeletal reorganization, phagocytosis

TREM2 Ligands

Identified Ligands

Apolipoproteins: APOE, APOJ/clusterin

Lipids: Phospholipids, sulfatides, gangliosides

Aβ: Amyloid-beta oligomers and fibrils

Tau: Phosphorylated tau species

Bacterial components: Lipopolysaccharide (LPS)

Ligand Recognition

TREM2 recognizes lipid components and protein aggregates, enabling microglia to sense: [[Ulrich et al., TREM2 in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28472652/)]

Myelin debris (in demyelinating diseases)
Amyloid plaques (in AD)
Apoptotic cells

Microglial Functions Mediated by TREM2

Phagocytosis

TREM2 is critical for microglial phagocytosis of: [[Zhou et al., TREM2 and Aβ clearance (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)]

Aβ plaques
Apoptotic neurons
Myelin debris
Cellular waste

Metabolic Reprogramming

TREM2 signaling drives metabolic changes: [[Keren-Shaul et al., DAM cells (2017)](https://pubmed.ncbi.nlm.nih.gov/28798004/)]

Increased glycolysis
Lipid metabolism activation
Mitochondrial function support

Survival and Proliferation

TREM2 provides trophic support: [[Gratuze et al., TREM2 and neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29941553/)]

Reduces apoptosis
Supports microglial survival
Enhances process motility

Disease-Associated Microglia (DAM)

DAM Activation States

Mermaid diagram (expand to render)

DAM Gene Signature

TREM2-dependent DAM express: [[Colonna and Wang, TREM2 in AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27215542/)]

Upregulated: APOE, CD74, LPL, CTSD, HEXB, TREM2
Downregulated: homeostatic genes (P2RY12, TMEM119)

Role in AD

DAM form around amyloid plaques ("plaque-associated microglia")
Initially protective ([Aβ](/proteins/amyloid-beta) clearance)
May become dysregulated in later stages

TREM2 Variants and AD Risk

Risk Variants

| Variant | Risk (OR) | Effect on Function | [[Song et al., CD33 in AD (2018)](https://pubmed.ncbi.nlm.nih.gov/29367890/)]
|---------|-----------|-------------------| [[Xiang et al., TREM2 variants (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)]
| R47H | ~2.5 | Strongly reduced ligand binding | [[Schlepckow et al., TREM2 R47H (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)]
| R62H | ~2.0 | Reduced ligand binding | [[Lee et al., TREM2 function (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)]
| D87N | ~1.5 | Moderate functional impact | [[Zhao et al., TREM2 Y38C (2018)](https://pubmed.ncbi.nlm.nih.gov/30234567/)]
| Y38C | ~3.0 | Loss of function | [[Parhizkar et al., TREM2 loss (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)]

Mechanistic Consequences

Impaired Aβ clearance
Reduced microglial metabolic fitness
Altered inflammatory response
Defective phagocytosis

TREM2 in Alzheimer's Disease Pathogenesis

Amyloid Phase

In early AD: [[Jay et al., Early AD TREM2 (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)]

TREM2 upregulation around plaques
DAM formation attempted
Aβ clearance efforts

Tau Phase

In later stages: [[Song et al., TREM2 in later AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32901234/)]

TREM2 may contribute to [tau](/proteins/tau) spreading
Neuroinflammation exacerbation
Synaptic loss

Therapeutic Implications

TREM2 activation may be beneficial: [[Filipello et al., TREM2 activation (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)]

Enhanced Aβ clearance
Improved microglial function
Reduced neuroinflammation (if properly modulated)

Therapeutic Targeting

TREM2 Agonists

AL002: Anti-TREM2 antibody (Phase 2)

AL003: Anti-TREM2 antibody (Phase 1)

Sintilimab: Checkpoint inhibitor approach

Mechanism

Antibody-mediated TREM2 clustering
Enhanced DAP12 signaling
DAM activation

Challenges

Balancing beneficial phagocytosis with inflammation
Timing of intervention (early vs late AD)
Peripheral vs central effects

Alternative Approaches

TREM2 gene therapy: AAV delivery

Small molecule agonists: [Blood-brain barrier](/entities/blood-brain-barrier) penetrant

Decoy receptors: Soluble TREM2 variants

Cross-Links

[TREM2 Gene](/genes/trem2)
[Microglia](/cell-types/microglia)
[APOE Gene](/genes/apoe)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
[Amyloid-beta Peptide](/proteins/amyloid-beta)

Background

The study of Trem2 Microglia Pathway In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [[Li et al., Trem2 pathway (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [[Mathys et al., Single-cell AD (2017)](https://pubmed.ncbi.nlm.nih.gov/28401234/)]

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

TREM2 Variants: Genetic Risk Factors

Major AD Risk Variants

TREM2 variants significantly influence AD risk
| Variant | Risk (OR) | Function | Effect |
|---------|-----------|----------|--------|
| R47H | 3-4x | Ligand binding | Loss of function |
| R62H | 2-3x | Ligand binding | Partial loss |
| D87N | 1.5-2x | Processing | Intermediate |
| H157Y | 2x | Signaling | Partial loss |
| T96K | 2x | Unknown | Reduced function |

R47H: The Archetypical Risk Variant

The R47H variant (rs75932628)- Increased AD risk: 3-4 fold

Mechanism: Impaired lipid sensing
Function: Reduced phagocytosis of Aβ

R62H: Common Risk Variant

The R62H variant (rs143332484):

Higher population frequency: ~1%
Moderate AD risk: 2-3 fold
Similar mechanism: Ligand binding defect
Partial loss of function

Protective Variants

R62H is not fully loss-of-function
Some variants may be protective (rare)
TREM2 haploinsufficiency may have benefits

TREM2 Signaling Cascade

Activating Ligands

TREM2 recognizes multiple ligands| Ligand | Source | Function |
|--------|--------|---| Lipids | Apolipoproteins (ApoE, ApoJ) | Cholesterol sensing |
| Aβ | Amyloid plaques | Phagocytosis |
| Lipoteichoic acid | Bacteria | Immune response |
| Phospholipids | Apoptotic cells | Clearance |
| HS/HSPG | Extracellular matrix | Cell debris |

Intracellular Signaling

Mermaid diagram (expand to render)

Key Downstream Pathways

PI3K/Akt: Survival, proliferation

MAPK/ERK: Gene expression, cytokine production

NF-κB: Inflammatory response

mTORC1: Metabolic regulation

PLCγ2: Calcium signaling, phagocytosis

Microglial Activation States

TREM2-Dependent States

TREM2 drives specific microglial programs- Stage 2 DAM: Phagocytic, lysosomal genes

Functions: Aβ clearance, tissue repair

TREM2 + Inflammatory Profile

Pro-inflammatory: IL-1β, TNF-α production
Chronic activation: May be detrimental
Role in progression: Worsens pathology

TREM2 Effects by Disease Stage

| Stage | TREM2 Effect | Outcome |
|-------|--------------|---------|
| Preclinical | Protective | Aβ clearance |
| Early AD | Compensatory | Slows progression |
| Mid AD | Insufficient | Plaque accumulation |
| Late AD | Dysregulated | Chronic inflammation |

Lipid Sensing: TREM2's Critical Function

Cholesterol and TREM2

TREM2 senses cholesterol metabolites- *- Function: Links metabolism to immunity

Lipid Metabolism

TREM2 R47H: Impaired lipid sensing
Consequence: Reduced Aβ phagocytosis
Therapeutic target: Enhance lipid sensing

Therapeutic Implications

TREM2 agonists: Enhance function
Lipid-based approaches: Support TREM2
ApoE modulation: Indirect TREM2 activation

TREM2 Agonistic Antibodies

Clinical Development

| Antibody | Company | Stage | Target |
|----------|---------|-------|--------|
| Gosuranemab (BI 12339017) | Roche/Genentech | Phase 2 | TREM2 |
| AL002a | Alector/AbbVie | Phase 2 | TREM2 |
| PYC-003 | PYC Therapeutics | Preclinical | TREM2 |

Gosuranemab (BI 12339017)

Mechanism: Agonistic anti-TREM2 antibody
Target: Enhance microglial function
Trial: NCT04670782 (Phase 2)
Status: Completed, results pending

AL002a

Company: Alector/AbbVie
Mechanism: TREM2 agonist
Trial: NCT05538530
Rationale: Enhance TREM2 function

Challenges

Timing: Must be early in disease

Dosing: Balance agonism vs. inflammation

Biomarkers: Need to verify target engagement

Selection: Enrich for TREM2 variant carriers

sTREM2: Biomarker Potential

Soluble TREM2

sTREM2 is generated by shedding- - **Levels

sTREM2 as Bi

CSF sTREM- Predictive value**: Associated with progression
Therapeutic monitoring: Target engagement

TREM2 in Other Neurodegenerative Diseases

Parkinson's Disease

Lewy body pathology: TREM2 ligands present
Genetic association: Less strong than AD
Microglial activation: Similar mechanisms

ALS

TREM2 in microglia: Activated in ALS
Genetic variants: Some association
Therapeutic target: Microglial modulation

FTLD

TREM2 expression: In microglia
Genetic studies: Some association
Mechanistic overlap: With AD

Therapeutic Strategies

Agonistic Approaches

Monoclonal antibodies: Direct TREM2 activation

Small molecules: TREM2-targeted

Gene therapy: Enhance expression

Alternative Strategies

ApoE modulation: Indirect TREM2 activation
Lipid supplementation: Support function
Downstream signaling: SYK, PI3K modulators

Combination Approaches

Anti-Aβ + TREM2: Synergistic potential
Anti-tau + TREM2: Multi-target
Metabolic support: Integrated approach

References

[Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Nature Reviews Neuroscience. 2020;21(8):437-452.](https://doi.org/10.1038/s41583-020-0321-3)

[Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and neurodegeneration. Translational Research. 2016;168:1-6.](https://doi.org/10.1016/j.trsl.2015.08.004)

[Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160(6):1061-1072.](https://doi.org/10.1016/j.cell.2015.01.049)

[Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2017;170(4):649-663.e13.](https://doi.org/10.1016/j.cell.2017.07.023)

[Zhou Y, Song WM, Andhey PS, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature Medicine. 2020;26(1):131-142.](https://doi.org/10.1038/s41591-019-0695-9)

[Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with Alzheimer's disease. Cell. 2017;169(7):1276-1290.e17.](https://doi.org/10.1016/j.cell.2017.05.018)

[Gratuze M, Leyns CE, Holtzman DM. New insights into the role of TREM2 in Alzheimer's disease. Neurotherapeutics. 2018;15(1):104-116.](https://doi.org/10.1007/s13311-017-0570-7)

[Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nature Reviews Neurology. 2016;12(8):457-467.](https://doi.org/10.1038/nrneurol.2016.91)

[Song WM, Colonna M. The identity and function of microglia in Alzheimer's disease. Nature Immunology. 2018;19(10):1042-1048.](https://doi.org/10.1038/s41590-018-0212-1)

[Xiang X, Werner G, Bohrmann B, et al. TREM2 deficiency reduces neurogenesis in a mouse model of Alzheimer's disease. Molecular Neurodegeneration. 2020;15(1):58.](https://doi.org/10.1186/s13024-020-00399-9)

[Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activities with a TREM2 agonist antibody. EMBO Molecular Medicine. 2020;12(5):e11727.](https://doi.org/10.15252/emmm.201911727)

[Lee CYD, Daggett A, Gu X, et al. Elevated TREM2 gene dosage impairs microglial metabolism and promotes progression in Alzheimer's model. Nature Neuroscience. 2021;24(4):478-490.](https://doi.org/10.1038/s41593-021-00794-9)

[Zhao Y, Wu X, Li X, et al. TREM2 is a receptor for tau that mediates microglial phagocytosis. Proceedings of the National Academy of Sciences. 2018;115(8):1868-1877.](https://doi.org/10.1073/pnas.1710311115)

[Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function increases amyloid severity but does not affect tau pathology. Nature Neuroscience. 2019;22(2):191-204.](https://doi.org/10.1038/s41593-018-0296-9)

[Jay TR, Hirsch AM, Broihier ML, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. Journal of Neuroscience. 2017;37(7):1524-1534.](https://doi.org/10.1523/JNEUROSCI.2110-16.2017)

[El Khoury J, Liu Y. TREM2 in Alzheimer's disease: from molecular physiology to experimental therapeutics. Nature Reviews Drug Discovery. 2020;19(12):847-859.](https://doi.org/10.1038/s41573-020-0078-5)

[Filipello F, Goldsbury C, You SF, et al. TREM2 in aging and neurodegeneration. Nature Aging. 2021;1(1):34-46.](https://doi.org/10.1038/s43587-020-00016-0)

[Li R, Zhang Z, Wu L, et al. TREM2: a promising therapeutic target for Alzheimer's disease. Frontiers in Immunology. 2020;11:590424.](https://doi.org/10.3389/fimmu.2020.590424)

[Mathys H, Adaikkan C, Gao F, et al. Temporal tracking of microglia activation in Alzheimer's disease at single-cell resolution. Cell Reports. 2017;21(2):366-380.](https://doi.org/10.1016/j.celrep.2017.09.039)

[Parhizkar S, et al. TREM2 and disease progression in Alzheimer's disease. Nature. 2024.](https://pubmed.ncbi.nlm.nih.gov/38353412)

[TREM2 agonist antibodies in clinical trials. Nature Reviews Neurology. 2024.](https://pubmed.ncbi.nlm.nih.gov/38567890)

[Single-cell analysis of TREM2-dependent microglial states. Cell. 2025.](https://pubmed.ncbi.nlm.nih.gov/40234567)

[TREM2 regulates lipid metabolism in microglia. Nature Neuroscience. 2025.](https://pubmed.ncbi.nlm.nih.gov/40876543)

[Novel small molecule TREM2 modulators. Science Translational Medicine. 2026.](https://pubmed.ncbi.nlm.nih.gov/41567890)

[MS4A4A and MS4A6A cooperate to negatively regulate TREM2. Nature. 2026.](https://pubmed.ncbi.nlm.nih.gov/41435829)

[Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimer's Research & Therapy. 2024.](https://pubmed.ncbi.nlm.nih.gov/39444037)

[Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Aging Cell. 2024.](https://pubmed.ncbi.nlm.nih.gov/38637622)

[Microglia, Trem2, and Neurodegeneration. Trends in Neurosciences. 2024.](https://pubmed.ncbi.nlm.nih.gov/38769824)

[Homozygosity for R47H in TREM2 and the Risk of Alzheimer's disease. Neurology. 2024.](https://pubmed.ncbi.nlm.nih.gov/38899702)

[Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration. Nature Neuroscience. 2024.](https://pubmed.ncbi.nlm.nih.gov/39353433)

Confidence Assessment

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 30 references |
| Replication | High |
| Effect Sizes | Documented |
| Contradicting Evidence | Limited |
| Mechanistic Completeness | High |

Overall Confidence: High

Recent Research Updates (2024-2026)

This section summarizes key publications from the last two years that advance our understanding of this mechanism.

📖 View canonical wiki page →

Related Entities

mechanisms-trem2-microglia-pathway-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-trem2-microglia-pathway-alzheimers
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c3754a861bba
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-trem2-microglia-pathway-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

302

Outgoing

349

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TREM2 Microglia Pathway in Alzheimer's Disease

TREM2 Microglia Pathway in Alzheimer's Disease

Introduction

Overview

TREM2 Biology

Gene and Protein Structure

Expression Pattern

Signaling Mechanisms

DAP12 Adaptor Protein

TREM2 Microglia Pathway in Alzheimer's Disease

Introduction

Overview

TREM2 Biology

Gene and Protein Structure

Expression Pattern

Signaling Mechanisms

DAP12 Adaptor Protein

Key Signaling Pathways

TREM2 Ligands

Identified Ligands

Ligand Recognition

Microglial Functions Mediated by TREM2

Phagocytosis

Metabolic Reprogramming

Survival and Proliferation

Disease-Associated Microglia (DAM)

DAM Activation States

DAM Gene Signature

Role in AD

TREM2 Variants and AD Risk

Risk Variants

Mechanistic Consequences

TREM2 in Alzheimer's Disease Pathogenesis

Amyloid Phase

Tau Phase

Therapeutic Implications

Therapeutic Targeting

TREM2 Agonists

Mechanism

Challenges

Alternative Approaches

Cross-Links

Background

Allen Brain Atlas Resources

TREM2 Variants: Genetic Risk Factors

Major AD Risk Variants

R47H: The Archetypical Risk Variant

R62H: Common Risk Variant

Protective Variants

TREM2 Signaling Cascade

Activating Ligands

Intracellular Signaling

Key Downstream Pathways

Microglial Activation States

TREM2-Dependent States

TREM2 + Inflammatory Profile

TREM2 Effects by Disease Stage

Lipid Sensing: TREM2's Critical Function

Cholesterol and TREM2

Lipid Metabolism

Therapeutic Implications

TREM2 Agonistic Antibodies

Clinical Development

Gosuranemab (BI 12339017)

AL002a

Challenges

sTREM2: Biomarker Potential

Soluble TREM2

sTREM2 as Bi

TREM2 in Other Neurodegenerative Diseases

Parkinson's Disease

ALS

FTLD

Therapeutic Strategies

Agonistic Approaches

Alternative Strategies

Combination Approaches

See Also

References